At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
BGB DXP593 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating BGB DXP593 and Placebo for Covid19. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The primary purpose of this study is to investigate the safety and tolerability of BGB-DXP593 administered intravenously as a single dose in healthy participants
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2020
Primary CompletionFeb 2021
TodayJul 2026
First PostedAug 31, 2020
Enrollment StartSep 8, 2020
Primary CompletionFeb 13, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.8 years ago
Interventions
BGB DXP593drug
Administered intravenously (IV) as specified in the treatment arm
Placebodrug
Placebo to match BGB-DXP593